CHIH


MSCI China Health Care ETF

Fund Summary

The Global X MSCI China Health Care ETF (CHIH) seeks to invest in large- and mid-capitalization segments of the MSCI China Index that are classified in the Health Care Sector as per the Global Industry Classification System (GICS).

Fund Objective

The Global X MSCI China Health Care ETF (CHIH) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI China Health Care 10/50 Index.

Why CHIH?

Targeted Exposure

CHIH is a targeted play on the Health Care Sector in China – the world’s second largest economy by GDP.

ETF Efficiency

In a single trade, CHIH delivers access to dozens of health care companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.

All Share Exposure

The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings, among others.

Fund Details As of 04/15/21

Key Facts

Ticker CHIH
Inception Date 12/07/18
CUSIP 37954Y541
ISIN US37954Y5419
Bloomberg Index Ticker NU722071
Primary Exchange NYSE Arca
Number of Holdings 87

Stats & Fees

Net Assets $23,792,429
Net Asset Value (NAV) $27.99
Shares Outstanding 850,002
Total Expense Ratio 0.65%

Distributions

30-Day SEC Yield 0.14%
Distribution Frequency Semi-Annually

Fund Prices As of 04/15/21

NAV $27.99 Daily Change -$0.06 -0.21%
Market Price $28.10 Daily Change $0.22 0.79%
30-Day Median Bid-Ask Spread 0.64%

Performance History

As of recent month & quarter-end (03/31/21)
As of recent month & quarter-end (03/31/21)
Fund NAV Market Price Index
1 Year 60.76% 63.89% 62.08%
Since Inception 30.47% 30.69% 31.47%
1 Year 60.76% 63.89% 62.08%
Since Inception 30.47% 30.69% 31.47%
Year-to-Date 2.19% 3.64% 2.35%
1 Month -3.03% -3.96% -2.95%
3 Months 2.19% 3.64% 2.35%
Since Inception 85.06% 85.80% 88.42%
Year-to-Date 2.19% 3.64% 2.35%
1 Month -3.03% -3.96% -2.95%
3 Months 2.19% 3.64% 2.35%
Since Inception 85.06% 85.80% 88.42%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 04/15/21

Return on Equity 9.50%
Weighted Avg. Market Cap 11,978 M
2020 2021
Price-to-earnings 61.58 44.07
Price-to-book value 4.33 4.07

Source: AltaVista Research, LLC

Fund Risk Stats As of 04/15/21

Versus Beta
S&P 500 0.54
MSCI EAFE 0.48
MSCI Emg. Mkts 0.71
Standard Deviation 24.60%

Source: AltaVista Research, LLC

Top Holdings As of 04/16/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
8.85 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 13.51 155,580 2,102,445.96
6.62 BGNE BEIGENE LTD-ADR BYYWPW6 305.54 5,149 1,573,225.46
5.96 241 HK ALIBABA HEALTH BRXVS60 2.86 494,600 1,416,334.73
5.94 ZLAB ZAI LAB LTD-ADR BD9GVY0 164.29 8,588 1,410,922.52
5.77 1093 HK CSPC PHARMACEUTI 6191997 1.23 1,111,008 1,371,252.93
5.58 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 1.04 1,278,600 1,326,329.77
4.99 1801 HK INNOVENT BIOLOGICS INC BGR6KX5 9.65 122,900 1,186,301.07
3.34 1833 HK PING AN HEALTHCA BDRYVB3 12.27 64,800 794,785.04
3.06 2359 HK WUXI APPTEC CO LTD-H BGHH0L6 20.22 35,980 727,476.75
2.96 3692 HK HANSOH PHARMACEU BJYKB72 4.61 152,700 703,564.37
2.65 1066 HK SHANDONG WEIG-H 6742340 1.98 318,400 630,247.56
2.19 853 HK MICROPORT SCIENTIFIC CORP B676TW7 6.34 82,200 521,026.52
2.17 600276 C1 JIANGSU HENGRU-A BP3R369 12.36 41,727 515,785.55
2.17 1099 HK SINOPHARM GROUP CO-H B3ZVDV0 2.85 180,800 515,411.30
2.14 300760 C2 SHENZHEN MINDR-A BHQK864 61.67 8,261 509,429.28
1.91 867 HK CHINA MEDICAL SY B6WY993 2.15 211,300 454,148.35
1.62 603259 C1 WUXI APPTEC CO LTD-A BHWLWV4 20.65 18,620 384,410.51
1.51 1951 HK JINXIN FERTILITY BJ9JY53 2.35 152,100 357,838.60
1.48 2196 HK FOSUN PHARMA-H B8XBQ96 4.70 75,100 352,788.63
1.39 300122 C2 CHONGQING ZHIF-A BD5CJY8 26.91 12,233 329,150.54
1.38 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.03 160,900 327,186.15
1.35 300015 C2 AIER EYE HSPTL-A BD5CLQ4 9.11 35,099 319,661.55
1.28 6185 HK CANSINO BIOLOGICS INC-H BJKDJS2 34.47 8,800 303,301.82
1.27 HCM HUTCHISON CH-ADR BYXV9H7 29.25 10,296 301,158.00
1.20 600436 C1 ZHANGZHOU PIEN-A BP3R7Z6 47.38 6,026 285,493.89
1.13 570 HK TRAD CHI MED 6971779 0.59 454,500 267,905.20
1.12 3759 HK PHARMARON BEIJ-H BK72QD3 18.62 14,350 267,240.46
1.09 2607 HK SHANGHAI PHARM-H B4Q4CJ6 2.06 125,500 259,077.60
1.01 3347 HK HANGZHOU TIGER-H BMZC7F8 17.23 13,920 239,884.17
0.94 000538 C2 YUNNAN BAIYAO-A BD5CP95 17.27 12,910 223,000.18
0.91 000661 C2 CHANGCHUN HIGH-A BD5CDB3 66.75 3,228 215,482.11
0.80 1530 HK 3SBIO INC BY9D3L9 0.90 211,200 189,727.86
0.80 3320 HK CHINA RESOURCES BYNGG26 0.65 290,700 189,685.78
0.73 2005 HK SSY GROUP LTD BYP9J68 0.64 271,100 172,709.61
0.65 000963 C2 HUADONG MEDICINE CO LTD-A BD5CM94 6.39 24,111 154,156.02
0.51 300347 C2 HANGZHOU TIGER-A BD5CCK5 20.56 5,916 121,637.13
0.51 600196 C1 SHANGHAI FOSUN-A BP3R3M5 6.58 18,374 120,941.07
0.48 600763 C1 TOPCHOICE MEDI-A BYYFJH8 42.85 2,680 114,848.63
0.48 300601 C2 SHENZHEN KANGT-A BFY8HT2 19.75 5,743 113,413.28
0.46 002007 C2 HUALAN BIOLOGI-A BD5CL19 6.56 16,670 109,341.64
0.44 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 7.71 13,700 105,656.88
0.44 002001 C2 ZHEJIANG NHU CO LTD-A BD5CH66 5.58 18,800 104,980.11
0.43 002044 C2 MEINIAN ONEHEA-A BD73L10 1.75 58,520 102,465.97
0.38 600332 C1 GUANGZHOU BAIY-A BP3R4Q6 4.22 21,459 90,512.65
0.37 300529 C2 JAFRON BIOMEDI-A BFY8H03 13.33 6,600 87,987.86
0.35 002821 C2 ASYMCHEM LABOR-A BD6V5C4 43.90 1,913 83,988.80
0.32 600998 C1 JOINTOWN PHARMACEUTICAL-A BP3R541 2.66 28,770 76,444.75
0.31 002294 C2 SHENZHEN SALUBRIS PHARM-A BD5CM05 5.44 13,700 74,463.94
0.30 002422 C2 SICHUAN KELUN-A BD5CL08 3.21 22,400 71,917.39
0.30 603882 C1 GUANGZHOU KING-A BFYX689 20.09 3,500 70,320.37
0.30 300003 C2 LEPU MEDICAL TECHNOLOGY-A BD5CM16 4.26 16,501 70,308.53
0.28 300595 C2 OVCTEK CHINA INC-A BHQPSJ2 14.91 4,532 67,561.52
0.26 600867 C1 TONGHUA DONGBA-A BP3R808 1.87 32,505 60,702.51
0.26 603858 C1 SHANDONG BUCHA-A BYW5NC3 3.35 18,087 60,593.66
0.25 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 19.45 3,033 58,989.14
0.24 000423 C2 DONG-E-E-JIAOCO LTD-A BD5CM61 5.52 10,300 56,852.42
0.24 600161 C1 BEIJING TIAN-A BP3R9J4 5.56 10,200 56,691.43
0.23 600079 C1 HUMANWELL HEAL-A BP3R712 5.03 11,000 55,302.32
0.23 300677 C2 INTCO MEDICAL-A BMTCVT6 22.82 2,400 54,769.67
0.22 1789 HK AK MEDICAL HOLDINGS LTD BFD6SZ0 1.22 42,700 52,152.59
0.21 601607 C1 SHANG PHARM -A BP3R4Z5 3.04 16,200 49,180.10
0.20 300558 C2 BETTA PHARMACE-A BD6QWL7 15.02 3,120 46,856.33
0.19 300253 C2 WINNING HEALTH-A BD5CKZ6 2.64 17,070 45,068.79
0.19 002603 C2 SHIJIAZHUANG Y-A BD5CHJ9 3.96 11,291 44,681.69
0.18 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.13 37,800 42,713.83
0.18 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 10.18 4,123 41,974.99
0.16 603658 C1 AUTOBIO DIAGNO-A BYW5N89 17.48 2,140 37,398.28
0.15 603707 C1 NANJING KING-F-A BF2DZL7 6.02 5,720 34,449.01
0.14 000739 C2 APELOA PHARMA-A BD5LY17 4.32 7,900 34,133.22
0.14 600521 C1 ZHEJIANG HUAHA-A BP3RBR6 2.89 11,310 32,635.59
0.13 300482 C2 GUANGZHOU WOND-A BFY8GZ1 13.21 2,300 30,390.90
0.12 000999 C2 CHINA RESOURCE-A BD5CL42 3.69 7,800 28,809.82
0.12 002019 C2 YIFAN PHARMACE-A BD5CDK2 2.79 10,200 28,494.28
0.12 002223 C2 JIANGSU YUYUE-A BD5CJM6 4.12 6,900 28,426.67
0.12 000513 C2 LIVZON PHARM-A BD5CQ25 6.44 4,400 28,320.72
0.12 600380 C1 JOINCARE PHARM-A BP3RBV0 2.06 13,700 28,231.18
0.12 002030 C2 DA AN GENE CO -A BD5CKW3 4.74 5,900 27,952.44
0.11 600201 C1 JINYU BIO-TECH-A BP3RBF4 3.11 8,600 26,714.50
0.11 600511 C1 CHINA NATIONAL-A BP3R9B6 5.08 5,200 26,437.91
0.10 300463 C2 MACCURA BIOTECH CO LTD-A BD5M283 6.59 3,700 24,382.45
0.10 600529 C1 SHANDONG PHAR-A BMVB2W1 6.09 4,000 24,353.93
0.10 002399 C2 SHENZHEN HEPAL-A BD5CKT0 2.65 8,500 22,520.18
0.09 000623 C2 JILIN AODONG P-A BD5CLG4 2.43 8,500 20,695.63
0.08 000028 C2 CHINA NATIONAL-A BD5CHT9 6.63 3,000 19,884.55
0.08 600566 C1 HUBEI JUMPCAN -A BS7K3N2 3.03 6,000 18,159.66
0.07 002773 C2 CHENGDU KANGHO-A BD5CM38 3.11 5,200 16,176.87
0.06 300026 C2 TIANJIN CHASE SUN PHARM-A BD5CGM5 0.61 23,500 14,340.36
0.02 CASH 0.98 5,227 5,139.12
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHIH is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by MSCI, nor does MSCI make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with MSCI.